
Chronic myeloid leukaemia Program in Pharmaceutical Benefits Scheme (PBS) 012-18051108

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

For information on how to process a PBS Authority, see Processing
Written Authority Required Listings . Contact a Program Support Officer
(PSO) if unsure on how to action an application.

On this Page:

Imatinib quick reference

Table 1

+-----------+-----------+-----------+-----------+-----------+-----------+
| Res       | Authority | PA        | P         | P         | P         |
| trictions | level and | a         | rocessing | rescriber | rescriber |
|           | section   | ssessment | system    | type      | s         |
|           |           |           |           |           | elf-serve |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Chronic   | Telephone | No        | OPA       | Not       | Yes       |
| phase     |           |           |           | specified |           |
|           | E         |           |           |           |           |
| First     | lectronic |           |           |           |           |
| line      |           |           |           |           |           |
|           | S85       |           |           |           |           |
| Initial   |           |           |           |           |           |
| and       |           |           |           |           |           |
| repeat    |           |           |           |           |           |
| initial   |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Chronic   | St        | No        | N/A       | Not       | N/A       |
| phase     | reamlined |           |           | specified |           |
|           |           |           |           |           |           |
| First     | S85       |           |           |           |           |
| line      |           |           |           |           |           |
|           |           |           |           |           |           |
| C         |           |           |           |           |           |
| ontinuing |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Chronic   | Telephone | No        | OPA       | Not       | Yes       |
| phase     |           |           |           | specified |           |
|           | E         |           |           |           |           |
| First     | lectronic |           |           |           |           |
| line      |           |           |           |           |           |
|           | S85       |           |           |           |           |
| Change    |           |           |           |           |           |
| from      |           |           |           |           |           |
| dasatinib |           |           |           |           |           |
| or        |           |           |           |           |           |
| nilotinib |           |           |           |           |           |
| for       |           |           |           |           |           |
| t         |           |           |           |           |           |
| oxicities |           |           |           |           |           |
| or        |           |           |           |           |           |
| int       |           |           |           |           |           |
| olerances |           |           |           |           |           |
| within    |           |           |           |           |           |
| the       |           |           |           |           |           |
| initial   |           |           |           |           |           |
| phase     |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Chronic   | St        | No        | N/A       | Not       | N/A       |
| phase     | reamlined |           |           | specified |           |
|           |           |           |           |           |           |
| First     | S85       |           |           |           |           |
| line      |           |           |           |           |           |
|           |           |           |           |           |           |
| Change    |           |           |           |           |           |
| from      |           |           |           |           |           |
| dasatinib |           |           |           |           |           |
| or        |           |           |           |           |           |
| nilotinib |           |           |           |           |           |
| for       |           |           |           |           |           |
| t         |           |           |           |           |           |
| oxicities |           |           |           |           |           |
| or        |           |           |           |           |           |
| int       |           |           |           |           |           |
| olerances |           |           |           |           |           |
| within    |           |           |           |           |           |
| the       |           |           |           |           |           |
| c         |           |           |           |           |           |
| ontinuing |           |           |           |           |           |
| phase     |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Ac        | Telephone | No        | OPA       | Not       | Yes       |
| celerated |           |           |           | specified |           |
| phase or  | E         |           |           |           |           |
| blast     | lectronic |           |           |           |           |
| phase     |           |           |           |           |           |
|           | S85       |           |           |           |           |
| First     |           |           |           |           |           |
| line      |           |           |           |           |           |
|           |           |           |           |           |           |
| Initial   |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Ac        | St        | No        | N/A       | Not       | N/A       |
| celerated | reamlined |           |           | specified |           |
| phase or  |           |           |           |           |           |
| blast     | S85       |           |           |           |           |
| phase     |           |           |           |           |           |
|           |           |           |           |           |           |
| First     |           |           |           |           |           |
| line      |           |           |           |           |           |
|           |           |           |           |           |           |
| C         |           |           |           |           |           |
| ontinuing |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+

Dasatinib quick reference

Table 2

+-----------+-----------+-----------+-----------+-----------+-----------+
| Res       | Authority | PA        | P         | P         | P         |
| trictions | level and | a         | rocessing | rescriber | rescriber |
|           | section   | ssessment | system    | type      | s         |
|           |           |           |           |           | elf-serve |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Chronic   | Telephone | No        | OPA       | Not       | Yes       |
| phase     |           |           |           | specified |           |
|           | E         |           |           |           |           |
| First     | lectronic |           |           |           |           |
| line      |           |           |           |           |           |
|           | S85       |           |           |           |           |
| Initial   |           |           |           |           |           |
| and       |           |           |           |           |           |
| repeat    |           |           |           |           |           |
| initial   |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Chronic   | St        | No        | N/A       | Not       | N/A       |
| phase     | reamlined |           |           | specified |           |
|           |           |           |           |           |           |
| First     | S85       |           |           |           |           |
| line      |           |           |           |           |           |
|           |           |           |           |           |           |
| C         |           |           |           |           |           |
| ontinuing |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Chronic   | Telephone | No        | OPA       | Not       | Yes       |
| phase     |           |           |           | specified |           |
|           | E         |           |           |           |           |
| First     | lectronic |           |           |           |           |
| line      |           |           |           |           |           |
|           | S85       |           |           |           |           |
| Change    |           |           |           |           |           |
| from      |           |           |           |           |           |
| imatinib  |           |           |           |           |           |
| or        |           |           |           |           |           |
| nilotinib |           |           |           |           |           |
| for       |           |           |           |           |           |
| t         |           |           |           |           |           |
| oxicities |           |           |           |           |           |
| or        |           |           |           |           |           |
| int       |           |           |           |           |           |
| olerances |           |           |           |           |           |
| within    |           |           |           |           |           |
| the       |           |           |           |           |           |
| initial   |           |           |           |           |           |
| phase     |           |           |           |           |           |
|           |           |           |           |           |           |
|           |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Chronic   | St        | No        | N/A       | Not       | N/A       |
| phase     | reamlined |           |           | specified |           |
|           |           |           |           |           |           |
| First     | S85       |           |           |           |           |
| line      |           |           |           |           |           |
|           |           |           |           |           |           |
| Change    |           |           |           |           |           |
| from      |           |           |           |           |           |
| imatinib  |           |           |           |           |           |
| or        |           |           |           |           |           |
| nilotinib |           |           |           |           |           |
| for       |           |           |           |           |           |
| t         |           |           |           |           |           |
| oxicities |           |           |           |           |           |
| or        |           |           |           |           |           |
| int       |           |           |           |           |           |
| olerances |           |           |           |           |           |
| within    |           |           |           |           |           |
| the       |           |           |           |           |           |
| c         |           |           |           |           |           |
| ontinuing |           |           |           |           |           |
| phase     |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Chronic,  | Telephone | No        | OPA       | Not       | Yes       |
| ac        |           |           |           | specified |           |
| celerated | E         |           |           |           |           |
| or blast  | lectronic |           |           |           |           |
| phase     |           |           |           |           |           |
|           | S85       |           |           |           |           |
| Second or |           |           |           |           |           |
| third     |           |           |           |           |           |
| line      |           |           |           |           |           |
|           |           |           |           |           |           |
| Initial   |           |           |           |           |           |
| and       |           |           |           |           |           |
| repeat    |           |           |           |           |           |
| initial   |           |           |           |           |           |
|           |           |           |           |           |           |
|           |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Chronic,  | St        | No        | N/A       | Not       | N/A       |
| ac        | reamlined |           |           | specified |           |
| celerated |           |           |           |           |           |
| or blast  | S85       |           |           |           |           |
| phase     |           |           |           |           |           |
|           |           |           |           |           |           |
| Second or |           |           |           |           |           |
| third     |           |           |           |           |           |
| line      |           |           |           |           |           |
|           |           |           |           |           |           |
| C         |           |           |           |           |           |
| ontinuing |           |           |           |           |           |
|           |           |           |           |           |           |
|           |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Chronic   | Telephone | No        | OPA       | Not       | Yes       |
| or        |           |           |           | specified |           |
| ac        | E         |           |           |           |           |
| celerated | lectronic |           |           |           |           |
| phase     |           |           |           |           |           |
|           | S85       |           |           |           |           |
| Second    |           |           |           |           |           |
| line      |           |           |           |           |           |
|           |           |           |           |           |           |
| Change    |           |           |           |           |           |
| from      |           |           |           |           |           |
| nilotinib |           |           |           |           |           |
| for       |           |           |           |           |           |
| t         |           |           |           |           |           |
| oxicities |           |           |           |           |           |
| or        |           |           |           |           |           |
| int       |           |           |           |           |           |
| olerances |           |           |           |           |           |
|           |           |           |           |           |           |
| Initial   |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Chronic   | St        | No        | N/A       | Not       | N/A       |
| phase     | reamlined |           |           | specified |           |
|           |           |           |           |           |           |
| Second    | S85       |           |           |           |           |
| line      |           |           |           |           |           |
|           |           |           |           |           |           |
| Change    |           |           |           |           |           |
| from      |           |           |           |           |           |
| nilotinib |           |           |           |           |           |
| for       |           |           |           |           |           |
| t         |           |           |           |           |           |
| oxicities |           |           |           |           |           |
| or        |           |           |           |           |           |
| int       |           |           |           |           |           |
| olerances |           |           |           |           |           |
|           |           |           |           |           |           |
| C         |           |           |           |           |           |
| ontinuing |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+

Nilotinib quick reference

Table 3

+-----------+-----------+-----------+-----------+-----------+-----------+
| Res       | Authority | PA        | P         | P         | P         |
| trictions | level and | a         | rocessing | rescriber | rescriber |
|           | section   | ssessment | system    | type      | s         |
|           |           |           |           |           | elf-serve |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Chronic   | Telephone | No        | OPA       | Not       | Yes       |
| phase     |           |           |           | specified |           |
|           | E         |           |           |           |           |
| First     | lectronic |           |           |           |           |
| line      |           |           |           |           |           |
|           | S85       |           |           |           |           |
| Initial   |           |           |           |           |           |
| and       |           |           |           |           |           |
| repeat    |           |           |           |           |           |
| initial   |           |           |           |           |           |
|           |           |           |           |           |           |
| 150mg     |           |           |           |           |           |
| only      |           |           |           |           |           |
|           |           |           |           |           |           |
|           |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Chronic   | St        | No        | N/A       | Not       | N/A       |
| phase     | reamlined |           |           | specified |           |
|           |           |           |           |           |           |
| First     | S85       |           |           |           |           |
| line      |           |           |           |           |           |
|           |           |           |           |           |           |
| C         |           |           |           |           |           |
| ontinuing |           |           |           |           |           |
|           |           |           |           |           |           |
| 150mg     |           |           |           |           |           |
| only      |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Chronic   | Telephone | No        | OPA       | Not       | Yes       |
| phase     |           |           |           | specified |           |
|           | E         |           |           |           |           |
| First     | lectronic |           |           |           |           |
| line      |           |           |           |           |           |
|           | S85       |           |           |           |           |
| Change    |           |           |           |           |           |
| from      |           |           |           |           |           |
| imatinib  |           |           |           |           |           |
| or        |           |           |           |           |           |
| dasatinib |           |           |           |           |           |
| for       |           |           |           |           |           |
| t         |           |           |           |           |           |
| oxicities |           |           |           |           |           |
| or        |           |           |           |           |           |
| int       |           |           |           |           |           |
| olerances |           |           |           |           |           |
| within    |           |           |           |           |           |
| the       |           |           |           |           |           |
| initial   |           |           |           |           |           |
| phase     |           |           |           |           |           |
|           |           |           |           |           |           |
| 150mg     |           |           |           |           |           |
| only      |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Chronic   | St        | No        | N/A       | Not       | N/A       |
| phase     | reamlined |           |           | specified |           |
|           |           |           |           |           |           |
| First     | S85       |           |           |           |           |
| line      |           |           |           |           |           |
|           |           |           |           |           |           |
| Change    |           |           |           |           |           |
| from      |           |           |           |           |           |
| imatinib  |           |           |           |           |           |
| or        |           |           |           |           |           |
| dasatinib |           |           |           |           |           |
| for       |           |           |           |           |           |
| t         |           |           |           |           |           |
| oxicities |           |           |           |           |           |
| or        |           |           |           |           |           |
| int       |           |           |           |           |           |
| olerances |           |           |           |           |           |
| within    |           |           |           |           |           |
| the       |           |           |           |           |           |
| c         |           |           |           |           |           |
| ontinuing |           |           |           |           |           |
| phase     |           |           |           |           |           |
|           |           |           |           |           |           |
| 150mg     |           |           |           |           |           |
| only      |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Chronic   | St        | No        | N/A       | Not       | N/A       |
| Phase     | reamlined |           |           | specified |           |
|           |           |           |           |           |           |
| First     | S85       |           |           |           |           |
| line      |           |           |           |           |           |
|           |           |           |           |           |           |
| C         |           |           |           |           |           |
| ontinuing |           |           |           |           |           |
|           |           |           |           |           |           |
| 150 mg    |           |           |           |           |           |
| only      |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Chronic   | St        | No        | N/A       | Not       | N/A       |
| Phase     | reamlined |           |           | specified |           |
|           |           |           |           |           |           |
| First     | S85       |           |           |           |           |
| line      |           |           |           |           |           |
|           |           |           |           |           |           |
| Gr        |           |           |           |           |           |
| andfather |           |           |           |           |           |
|           |           |           |           |           |           |
| 200 mg    |           |           |           |           |           |
| only      |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Chronic   | Telephone | No        | OPA       | Not       | Yes       |
| or        |           |           |           | specified |           |
| ac        | E         |           |           |           |           |
| celerated | lectronic |           |           |           |           |
| phase     |           |           |           |           |           |
|           | S85       |           |           |           |           |
| Second or |           |           |           |           |           |
| third     |           |           |           |           |           |
| line      |           |           |           |           |           |
|           |           |           |           |           |           |
| Initial   |           |           |           |           |           |
| and       |           |           |           |           |           |
| repeat    |           |           |           |           |           |
| initial   |           |           |           |           |           |
|           |           |           |           |           |           |
| 200mg     |           |           |           |           |           |
| only      |           |           |           |           |           |
|           |           |           |           |           |           |
|           |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Chronic   | St        | No        | N/A       | Not       | N/A       |
| phase     | reamlined |           |           | specified |           |
|           |           |           |           |           |           |
| Second or | S85       |           |           |           |           |
| third     |           |           |           |           |           |
| line      |           |           |           |           |           |
|           |           |           |           |           |           |
| C         |           |           |           |           |           |
| ontinuing |           |           |           |           |           |
|           |           |           |           |           |           |
| 200mg     |           |           |           |           |           |
| only      |           |           |           |           |           |
|           |           |           |           |           |           |
|           |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Chronic   | Telephone | No        | OPA       | Not       | Yes       |
| or        |           |           |           | specified |           |
| ac        | E         |           |           |           |           |
| celerated | lectronic |           |           |           |           |
| phase     |           |           |           |           |           |
|           | S85       |           |           |           |           |
| Second    |           |           |           |           |           |
| line      |           |           |           |           |           |
|           |           |           |           |           |           |
| Change    |           |           |           |           |           |
| from      |           |           |           |           |           |
| dasatinib |           |           |           |           |           |
| for       |           |           |           |           |           |
| t         |           |           |           |           |           |
| oxicities |           |           |           |           |           |
| or        |           |           |           |           |           |
| int       |           |           |           |           |           |
| olerances |           |           |           |           |           |
| within    |           |           |           |           |           |
| the       |           |           |           |           |           |
| initial   |           |           |           |           |           |
| phase     |           |           |           |           |           |
|           |           |           |           |           |           |
| 200 mg    |           |           |           |           |           |
| only      |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Chronic   | St        | No        | N/A       | Not       | N/A       |
| Phase     | reamlined |           |           | specified |           |
|           |           |           |           |           |           |
| Second    | S85       |           |           |           |           |
| line      |           |           |           |           |           |
|           |           |           |           |           |           |
| Change    |           |           |           |           |           |
| from      |           |           |           |           |           |
| dasatinib |           |           |           |           |           |
| for       |           |           |           |           |           |
| t         |           |           |           |           |           |
| oxicities |           |           |           |           |           |
| or        |           |           |           |           |           |
| int       |           |           |           |           |           |
| olerances |           |           |           |           |           |
| within    |           |           |           |           |           |
| the       |           |           |           |           |           |
| c         |           |           |           |           |           |
| ontinuing |           |           |           |           |           |
| phase     |           |           |           |           |           |
|           |           |           |           |           |           |
| 200 mg    |           |           |           |           |           |
| only      |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+

Ponatinib quick reference

Table 4

+-----------+-----------+-----------+-----------+-----------+-----------+
| Res       | Authority | PA        | P         | P         | P         |
| trictions | level and | a         | rocessing | rescriber | rescriber |
|           | section   | ssessment | system    | type      | s         |
|           |           |           |           |           | elf-serve |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Initial   | Written   | No        | OPA       | Not       | Yes       |
| and       |           |           |           | specified |           |
| repeat    | E         |           |           |           |           |
| initial   | lectronic |           |           |           |           |
|           |           |           |           |           |           |
| PB171     | S85       |           |           |           |           |
| form      |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| First     | Written   | No        | OPA       | Not       | Yes       |
| c         |           |           |           | specified |           |
| ontinuing | E         |           |           |           |           |
|           | lectronic |           |           |           |           |
| PB084     |           |           |           |           |           |
| form      | S85       |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| S         | Telephone | No        | OPA       | Not       | Yes       |
| ubsequent |           |           |           | specified |           |
| c         | E         |           |           |           |           |
| ontinuing | lectronic |           |           |           |           |
|           |           |           |           |           |           |
|           | S85       |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+

                                   

-   Services Australia ABN 90 794 605 008 
